SK Capital appoints new MD and Director


SK Capital Partners, a private investment firm focused on the specialty materials, chemicals and pharmaceuticals sectors, has promoted Stephen d’Incelli to Managing Director and appointed Lee Karras as a Director.

Previously a Principal at SK Capital, d’Incelli has played a significant role in sourcing and executing acquisitions as well as guiding portfolio companies where he serves as a member of numerous Boards of Directors. Prior to joining SK Capital in 2015, d’Incelli was a Vice President at Sun Capital Partners where he was involved in a variety of acquisitions including corporate carve-outs, entrepreneurial transitions and add-on acquisitions. Before joining Sun Capital, he worked in the Global Leveraged Finance group at Lehman Brothers. 
 
Karras recently joined SK Capital as a Director where he will be providing guidance to SK Capital portfolio companies in the pharmaceuticals sector as well as helping find and evaluate new investment opportunities.
 
Karras has spent the past seven years running SK Capital portfolio companies, most recently in highly successful roles serving as CEO of Halo Pharmaceuticals Inc, and previously as President of IBA Molecular North America. Prior to IBA Molecular, Karras was President and CEO of AAIPharma Services Company where he led the company’s transition from bankruptcy to a successful exit in 2009.  Prior to AAI, Karras held various positions at Baxter Healthcare and Cook Medical where he served as General Manager and helped build the pharmaceutical services start up into a sizeable sterile injectable pharma services business. 
 

Furtherreading
from Private Equity Wire

Atrato appoints senior adviser

Mon 18/03/2019 - 10:35

Activa Capital appoints CFO

Mon 18/03/2019 - 10:33

specialreports
other gfm publications
GFM corporate logo